Monoclonal antibodies as oncological treatment: literature review for cancer patient service and management of infusion reactions
DOI:
https://doi.org/10.17696/2318-3691.26.3.2019.1369Keywords:
Integrative oncology; Antineoplastic protocols; Infusions, parenteral; Drug administration schedule; Molecular targeted therapyAbstract
Introduction: This study aims to analyse differences among monoclonal antibodies, their oncological indications, and challenges of professional management of their infusion reactions. Objective: To identify, based on the literature, how to manage infusion reactions related to monoclonal antibodies; describe a care protocol for infusion reaction; identify monoclonal antibodies that have higher incidence of infusion reactions. Methods: A systematic review of the literature was done based on the Bireme, PubMed, Web of Science, Scopus, Cinahl, and Embase databases, covering papers published from 2011 to 2017, using the keywords: monoclonal antibodies, care protocol, infusion reactions, and oncological treatment. Results: The reactions are described with greater risk during the first exposure to drug. Patients receiving intravenous pre-medication with glucocorticoids have less probability of reactions. Most patients have a remarkable tolerance about subsequent infusions using pre-medication. Advanced age, poor prognosis, obesity, and absence of corticosteroid prophylaxis are risk factors for having a reaction. Care protocol of infusion reaction includes: (i) explain procedure to the patient; (ii) inform patients about the treatment and stimulate the “self-monitoring”; (iii) ensure all employees know which patients are receiving their first infusion and the associated risks; (iv) perform infusion in a room with resuscitation equipment; (v) standardized patient evaluation, highlighting risk factors for infusion reactions that may get worse results; (vi) use the lowest dosage of the drug and the lowest infusion rate; (vii) start intravenous pre-medication with glucocorticoids; (viii) administrate analgesic/antihistamine drugs; (ix) evaluate the patient every 15 minutes. Conclusion: It is extremely important that all professionals know how to recognize an infusion reaction and how to manage it. Therefore, this protocol can improve patient care. In addition, the patient himself should be informed how to identify alterations during the infusion.
References
Del Debbio CB, Tonon LM, Secoli SR. TERAPIA COM ANTICORPOS MONOCLONAIS: uma revisão de literatura. Revista Gaúcha de Enfermagem. 2007;28(1):133-42.
Casanova Estruch B. Safety profile and practical considerations of monoclonal antibody treatment. Neurologia. 2013;28(3):169-78.
Freeman CL, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T, et al. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood. 2015;126(24):2646-9.
Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015;373(13):1207-19.
Radford J, Davies A, Cartron G, Morschhauser F, Salles G, Marcus R, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 2013;122(7):1137-43.
Santos R, Lima P, Nitsche A, Harth F, Melo F, Akamatsu H. Aplicações terapêuticas dos anticorpos monoclonais. Revista Brasileira de Alergia e Imunopatologia. 2006;29(2):77-85.
Clark O, Fanti L, Donato B, Amaral LM, Santinho C, Bernardino G. Valor clínico das terapias biológicas em oncologia: mensuração de desfechos para a avaliação de benefícios. Jornal Brasileiro de Economia da Saúde. 2013;5(1):29-37.
Snowden A, Hayden I, Dixon J, Gregory G. Prevention and management of obinutuzumab-associated toxicities: Australian experience. Int J Nurs Pract. 2015;21 Suppl 3:15-27.
Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, et al. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. J Clin Oncol. 2015;33(30):3467-74.
Morschhauser FA, Cartron G, Thieblemont C, Solal-Céligny P, Haioun C, Bouabdallah R, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2912-9.
Jean GW, Comeau JM. Role of obinutuzumab in the treatment of chronic lymphocytic leukemia. Am J Health Syst Pharm. 2015;72(11):933-42.
Sehn LH, Assouline SE, Stewart DA, Mangel J, Gascoyne RD, Fine G, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood. 2012;119(22):5118-25.
Dotson E, Crawford B, Phillips G, Jones J. Sixty-minute infusion rituximab protocol allows for safe and efficient workflow. Support Care Cancer. 2016;24(3):1125-9.
Patel J, Ho M, Ho V, Bello C, Djulbegovic B, Sokol L, et al. Rapid infusion rituximab for maintenance therapy: is it feasible? Leuk Res Treatment. 2013;2013:629283.
Norin S, Björkstrand B, Rommel F, Timberg L, Andersson PO, Häggström J, et al. Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study. Leuk Res. 2015;39(1):33-7.
Mir O, Alexandre J, Coriat R, Ropert S, Boudou-Rouquette P, Bui T, et al. Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients. Invest New Drugs. 2012;30(4):1756-60.
Shah SR, Gressett Ussery SM, Dowell JE, Marley E, Liticker J, Arriaga Y, et al. Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension. Ann Oncol. 2013;24(4):960-5.
Moreau P, van de Donk NW, San Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, et al. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Drugs. 2016;76(8):853-67.
Chang PH, Huang JS. Successful rechallenge of cetuximab following severe infusion-related reactions: a case report. Chin J Cancer Res. 2014;26(1):E10-2.
Emani MK, Zaiden RA. Aseptic meningitis: a rare side effect of cetuximab therapy. J Oncol Pharm Pract. 2013;19(2):178-80.
Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ, et al. Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist. 2014;19(3):228-34.
Momtaz P, Park V, Panageas KS, Postow MA, Callahan M, Wolchok JD, et al. Safety of Infusing Ipilimumab Over 30 Minutes. J Clin Oncol. 2015;33(30):3454-8.
Emery P, Rigby W, Tak PP, Dörner T, Olech E, Martin C, et al. Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program. PLoS One. 2014;9(2):e87379.
Baxley AA, Kumm DE, Bishop CB, Medina PJ, Holter-Chakrabarty J. Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantation. J Oncol Pharm Pract. 2013;19(3):279-83.
Delord JP, Tabernero J, García-Carbonero R, Cervantes A, Gomez-Roca C, Bergé Y, et al. Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. Eur J Cancer. 2014;50(3):496-505.
Gallimore E. Infusion-related risks associated with chemotherapy. Nurs Stand. 2016;30(25):51-60.
Salzberg M. First-in-Human Phase 1 Studies in Oncology: The New Challenge for Investigative Sites. Rambam Maimonides Med J. 2012;3(2):e0007.
Monem EA, Al-Bahrani B, Mehdi I, Nada A. Rapid rituximab infusion, local center experience. Gulf J Oncolog. 2013;1(14):52-6.
Patel SP, Woodman SE. Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther. 2011;5:489-95.
Hanaizi Z, van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, et al. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer. 2012;48(2):237-42.
Tuthill M, Crook T, Corbet T, King J, Webb A. Rapid infusion of rituximab over 60 min. Eur J Haematol. 2009;82(4):322-5.
Vey N, Delaunay J, Martinelli G, Fiedler W, Raffoux E, Prebet T, et al. Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. Oncotarget. 2016;7(22):32532-42.
Arosa FA, Cardoso EM, Pacheco FC. Fundamentos de Imunologia. 2 ed. Lisboa2012.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
